The Food and Drug Administration’s (FDA) proposed rule on the regulation of Laboratory Developed Tests (LDTs), published on October 3rd, has garnered significant attention. This move came after Congress failed to enact the Verifying Accurate, Leading-edge IVCT Development Act (VALID) last year. The VALID Act endorsed by the FDA aimed to address LDT regulation within the framework of a broader overhaul of in vitro diagnostics (IVD) regulation.
An LDT is a type of in vitro diagnostic test designed, developed, and validated within one laboratory. These tests are often used for rare diseases and conditions, thus playing a critical role in healthcare delivery.
The FDA has long asserted the need for a stronger oversight framework for LDTs, arguing that the current system is not in line with the complexity and critical function of these tests. This shift in attention from congressional legislation to regulatory rules signals the agency’s continued commitment to reinforcing LDT regulation.
Akin Gump Strauss Hauer & Feld LLP provided a detailed analysis of the proposed rule. They highlighted that the proposed rule, although not yet finalized, represents more than just an extension of pre-existing FDA policies. Rather, it introduces a new regulatory paradigm for LDTs, which portends significant changes in the laboratory testing field.
As the FDA moves forward with this proposed rule, it will be crucial for legal professionals working with healthcare corporations and labs to understand its implications. The proposed changes will potentially transform LDTs regulation, which will undoubtedly impact the scope and habits of many medical diagnostic entities.